Curanex Pharmaceuticals regained Nasdaq Listing Rule 5550 compliance after its common stock maintained a closing bid price of at least $1.00 per share. The determination closes the listing matter, meaning Curanex satisfied the minimum-bid-price requirement described in the company update and remains compliant with that Nasdaq rule.

Key Highlights

  • Curanex completed a Reverse Stock Split on August 20, 2026.
  • Nasdaq Staff notified Curanex of the compliance determination on September 3, 2026.
  • Curanex’s update was signed by Chief Executive Officer Jun Liu on September 4, 2026.

Curanex Pharmaceuticals Inc. (NASDAQ: CURX) regained compliance with Nasdaq’s minimum-bid-price requirement after its common stock maintained a closing bid of at least $1.00 per share. Nasdaq Staff determined that the listing issue was resolved, and the matter is now closed.

Reverse Stock Split Preceded Nasdaq Resolution

Curanex carried out a reverse stock split of its outstanding common stock on August 20, 2026, with the stated purpose of restoring compliance with Nasdaq Listing Rule 5550. The action followed a November 5, 2025 notification that the company had fallen below Nasdaq’s minimum bid-price standard over the required business-day period. Nasdaq Staff delivered its compliance determination on September 3, 2026. The company’s update identified the closing bid price as the measure used to assess compliance.

Listing Matter Closed

The Nasdaq determination returned Curanex to compliance with Listing Rule 5550. The company said the matter is closed following the finding that its common stock had met the $1.00-per-share threshold. Chief Executive Officer Jun Liu signed the update for Curanex Pharmaceuticals on September 4, 2026. The signature was made under the requirements of the Securities Exchange Act of 1934.